NetworkNewsBreaks – FDA Accepts Filing of Intellipharmaceutics’ (NASDAQ: IPCI) NDA for Rexista™; Aegis Reiterates ‘Buy’ Rating and $8 PT
Shares of Intellipharmaceutics International (NASDAQ: IPCI) are slightly higher following news late yesterday that the FDA has accepted the company’s filing of a New Drug Application (NDA) for Rexista™ for the management of moderate to severe pain. Pivotal pharmacokinetic and abuse-deterrent studies have shown Intellipharmaceutics’ Rexista as bioequivalent to OxyContin®. "The acceptance of filing of our NDA for Rexista™ represents an important step towards the commercialization of a potentially best–in-class abuse-deterrent oxycodone hydrochloride extended release product. We look forward to working with the FDA during their review of our NDA submission," Intellipharmaceutics CEO Dr. Isa Odidi stated in the news…